GO:0090155 negative regulation of sphingolipid biosynthetic process: Metabolic Control, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0090155 describes any process that decreases the rate, frequency or extent of sphingolipid biosynthesis, the pathway that produces sphingosine-based lipids such as ceramides and sphingomyelins.
• The ORMDL proteins (ORMDL1, ORMDL2, ORMDL3) are central negative regulators of de novo sphingolipid biosynthesis, forming a conserved complex with serine palmitoyltransferase (SPT).
• Sphingosine kinase-1 (SPHK1) and ORMDL proteins functionally interact to tune flux through the sphingolipid biosynthetic pathway.
• Dysregulation of negative regulation of sphingolipid biosynthesis contributes to macular disease and peripheral neuropathy, as shown by rare SPTLC1 variants that escape ORMDL-mediated inhibition.
• Sphingolipid metabolic remodeling, including altered ceramide homeostasis, controls functional maturation of human pluripotent stem cell-derived beta cells.
• CRISPR knockout, point-mutation, knock-in and overexpression models are essential to dissect causal roles of ORMDL, SPHK1, SPTLC1 and related genes in this process.
Description
Sphingolipids are a class of bioactive lipids that include ceramides, sphingomyelins, glycosphingolipids and sphingosine-1-phosphate, and they participate in membrane structure, cell signaling and metabolic homeostasis. The biosynthetic route that generates these molecules is tightly controlled, and the Gene Ontology term GO:0090155, negative regulation of sphingolipid biosynthetic process, captures the regulatory inputs that reduce the rate, frequency or extent of sphingolipid biosynthesis. This term is of high interest because unrestrained sphingolipid production is linked to metabolic, retinal, vascular and intestinal disorders. Mechanistically, the best-characterized negative regulators of sphingolipid biosynthesis are the ORMDL proteins, which associate with serine palmitoyltransferase (SPT) and limit de novo sphingolipid synthesis. Sphingosine kinase-1 (SPHK1) also participates in this regulatory circuit, and its activity influences the balance between sphingolipid species. In addition, specialized cell types such as retinal endothelial cells and vascular smooth muscle cells display distinct sphingolipid metabolic signatures, indicating that negative regulation of sphingolipid biosynthesis is cell-type specific. For researchers, GO:0090155 provides a framework to interpret genetic, pharmacological and metabolic data. Loss-of-function or gain-of-function experiments on ORMDL genes, SPHK1, SPTLC1 and related enzymes can be mapped directly to this term, enabling mechanistic studies of disease-associated sphingolipid dysregulation. This article summarizes the definition, core biology, key genes, disease links and experimental methods relevant to GO:0090155.
negative regulation of sphingolipid biosynthetic process At A Glance
| GO ID | GO:0090155 |
|---|---|
| GO term | negative regulation of sphingolipid biosynthetic process |
| Ontology | biological_process |
| Synonym | negative regulation of sphingolipid biosynthesis involved in cellular sphingolipid homeostasis |
| Definition | Any process that decreases the rate, frequency or extent of sphingolipid biosynthesis, the chemical reactions and pathways resulting in the formation of sphingolipids containing sphingosine or a closely related base. |
| Major function | Limits de novo sphingolipid production to maintain cellular sphingolipid homeostasis and prevent lipotoxicity. |
| Key regulators | ORMDL1, ORMDL2, ORMDL3, SPHK1, SPTLC1, SPTLC2, SPTSSA, SPTSSB |
| Related pathway | Sphingolipid de novo biosynthesis and ceramide homeostasis |
| Disease relevance | Macular disease, peripheral neuropathy, diabetic retinopathy, osteosarcoma, intestinal inflammation, beta cell dysfunction |
What Is GO:0090155?
GO:0090155, negative regulation of sphingolipid biosynthetic process, is defined as any process that decreases the rate, frequency or extent of sphingolipid biosynthesis. Sphingolipid biosynthesis is the set of chemical reactions and pathways that produce sphingolipids, which are lipids containing the long-chain amine diol sphingosine or a closely related sphingoid base. The term is a biological process and includes the synonym negative regulation of sphingolipid biosynthesis involved in cellular sphingolipid homeostasis. In practice, this term covers molecular mechanisms such as inhibition of serine palmitoyltransferase activity by ORMDL proteins, feedback control by sphingolipid intermediates, and regulatory interactions involving sphingosine kinase-1.
Why Is negative regulation of sphingolipid biosynthetic process Important in Cell Biology?
Negative regulation of sphingolipid biosynthetic process is important because sphingolipids are potent bioactive molecules, and their overproduction can drive cellular stress, inflammation, insulin resistance and neurodegeneration. The ORMDL-SPT axis is a conserved rheostat that prevents excessive de novo sphingolipid synthesis, and disruption of this brake is associated with human disease. Understanding GO:0090155 therefore informs therapeutic strategies that aim to restore sphingolipid balance in metabolic, retinal, vascular and intestinal disorders.
• Maintains cellular sphingolipid homeostasis by preventing excessive de novo synthesis.
• Protects against ceramide and sphingolipid lipotoxicity in metabolic tissues.
• Modulates intestinal homeostasis and host-microbe symbiosis through Bacteroides-derived sphingolipids.
• Contributes to blood-retina barrier function in diabetic retinopathy.
• Is linked to macular disease and peripheral neuropathy through SPTLC1 variants that escape ORMDL inhibition.
• Influences osteosarcoma risk stratification through sphingolipid metabolism signatures.
• Shapes vascular smooth muscle cell heterogeneity in carotid artery and abdominal aorta.
• Provides a mechanistic target for pharmacological modulation of sphingolipid flux.
• Is essential for functional maturation of human pluripotent stem cell-derived beta cells via ceramide remodeling.
• Offers a conceptual framework for CRISPR-based causal gene validation in sphingolipid-related diseases.
What Happens During negative regulation of sphingolipid biosynthetic process?
ORMDL-mediated inhibition of serine palmitoyltransferase
In simple terms: ORMDL proteins act like a brake on the first committed step of sphingolipid production.
The ORMDL proteins (ORMDL1, ORMDL2 and ORMDL3) form a complex with serine palmitoyltransferase (SPT) and reduce its catalytic activity, thereby decreasing de novo sphingolipid biosynthesis. This inhibition is a key mechanism of GO:0090155 and is conserved from yeast to humans. ORMDL proteins are also implicated in metabolic health and disease, underscoring their physiological importance.
Sphingosine kinase-1 and feedback control
In simple terms: Sphingosine kinase-1 helps set the balance between sphingolipid building blocks and their downstream products.
Sphingosine kinase-1 (SPHK1) functionally interacts with ORMDL proteins to regulate de novo sphingolipid biosynthesis. This interaction contributes to feedback control, where changes in sphingolipid metabolite levels adjust the rate of biosynthesis. The coordination between SPHK1 and ORMDL proteins is part of the negative regulatory arm captured by GO:0090155.
Ceramide homeostasis and metabolic remodeling
In simple terms: Cells continuously adjust ceramide levels to match their functional state.
Remodeling ceramide homeostasis promotes functional maturation of human pluripotent stem cell-derived beta cells, indicating that negative regulation of sphingolipid biosynthesis is coupled to developmental and metabolic transitions. This suggests that GO:0090155 is not merely a housekeeping brake but a dynamic process that responds to cellular differentiation cues.
Cell-type-specific sphingolipid regulation
In simple terms: Different cells use different sphingolipid settings.
Specialized retinal endothelial cells modulate the blood-retina barrier in diabetic retinopathy through sphingolipid-related mechanisms. Similarly, vascular smooth muscle cells from common carotid artery and abdominal aorta display heterogeneity in sphingolipid metabolism. These findings indicate that negative regulation of sphingolipid biosynthesis is context-dependent and tissue-specific.
Host-microbe and intestinal sphingolipid control
In simple terms: Gut bacteria can influence sphingolipid levels and intestinal health.
Bacteroides-derived sphingolipids are critical for maintaining intestinal homeostasis and symbiosis, and host regulation of sphingolipid biosynthesis contributes to this balance. Negative regulation of sphingolipid biosynthetic process therefore has implications for microbiome-host interactions and intestinal inflammation.
Key Genes Involved in GO:0090155 negative regulation of sphingolipid biosynthetic process
The following genes and proteins are experimentally linked to negative regulation of sphingolipid biosynthetic process (GO:0090155) and its downstream biology.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ORMDL1 | Inhibits serine palmitoyltransferase and reduces de novo sphingolipid synthesis | Core negative regulator; knockout increases sphingolipid flux |
| ORMDL2 | ORMDL family member that limits sphingolipid biosynthesis | Modulates sphingolipid homeostasis; candidate for metabolic studies |
| ORMDL3 | ORMDL family member associated with metabolic and inflammatory phenotypes | Linked to metabolic health and disease; target for functional validation |
| SPHK1 | Sphingosine kinase-1; interacts with ORMDL proteins to regulate sphingolipid biosynthesis | Balances sphingosine-1-phosphate and ceramide levels |
| SPTLC1 | Catalytic subunit of serine palmitoyltransferase; target of ORMDL inhibition | Variants escape ORMDL inhibition and cause neuropathy/macular disease |
| SPTLC2 | Serine palmitoyltransferase subunit | Component of the SPT complex regulated by ORMDL proteins |
| SPTSSA | Small subunit of serine palmitoyltransferase | Modulates SPT activity and sphingolipid synthesis |
| SPTSSB | Small subunit of serine palmitoyltransferase | Regulates SPT complex function |
| CERS1 | Ceramide synthase 1 | Ceramide homeostasis and beta cell maturation |
| CERS2 | Ceramide synthase 2 | Ceramide remodeling in metabolic tissues |
| CERS4 | Ceramide synthase 4 | Sphingolipid diversity and signaling |
| DEGS1 | Dihydroceramide desaturase | Controls ceramide species balance |
| SMPD1 | Acid sphingomyelinase | Sphingomyelin catabolism and ceramide generation |
| ASAH1 | Acid ceramidase | Ceramide-to-sphingosine conversion |
| SGMS1 | Sphingomyelin synthase 1 | Sphingomyelin biosynthesis and homeostasis |
| UGCG | Glucosylceramide synthase | Glycosphingolipid biosynthesis |
| B4GALT5 | Lactosylceramide synthase | Glycosphingolipid pathway |
| B4GALT6 | Lactosylceramide synthase | Glycosphingolipid pathway |
How Is negative regulation of sphingolipid biosynthetic process Regulated?
Negative regulation of sphingolipid biosynthetic process is controlled by a conserved feedback circuit in which ORMDL proteins sense sphingolipid levels and inhibit serine palmitoyltransferase. Sphingosine kinase-1 interacts with this circuit to modulate flux. In addition, cell-type-specific signals, such as those operating in retinal endothelial cells and vascular smooth muscle cells, adjust sphingolipid metabolism. Ceramide remodeling during beta cell maturation further indicates developmental regulation of this process. Together, these layers ensure that sphingolipid biosynthesis is matched to cellular demand and stress.
negative regulation of sphingolipid biosynthetic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SPTLC1 | Macular disease and peripheral neuropathy | Knock-in of patient variants in iPSC-derived retinal or neuronal cells |
| ORMDL3 | Metabolic and inflammatory phenotypes | Knockout and overexpression in hepatocytes or immune cells |
| SPHK1 | Sphingolipid imbalance and metabolic stress | Point-mutation of catalytic residues in cancer or metabolic cell lines |
| CERS1/CERS2 | Beta cell maturation and ceramide homeostasis | Knockout in human pluripotent stem cell-derived beta cells |
| Bacteroides sphingolipid genes | Intestinal homeostasis and symbiosis | Gnotobiotic mouse models with bacterial mutants |
Macular disease and peripheral neuropathy
Rare variants in SPTLC1 that escape ORMDL-mediated inhibition cause dysregulated sphingolipid biosynthesis and are associated with macular disease and peripheral neuropathy. This demonstrates that loss of negative regulation of sphingolipid biosynthetic process can directly drive human degenerative disease.
Diabetic retinopathy and vascular biology
Specialized retinal endothelial cells modulate the blood-retina barrier in diabetic retinopathy, and sphingolipid metabolism contributes to this process. Heterogeneity of common carotid artery and abdominal aorta vascular smooth muscle cells also involves sphingolipid metabolic differences. These findings link GO:0090155 to vascular complications.
Osteosarcoma and metabolic risk stratification
Bayesian optimization-enhanced machine learning for osteosarcoma risk stratification has identified sphingolipid metabolism signatures, suggesting that negative regulation of sphingolipid biosynthesis is relevant to cancer risk modeling.
Intestinal homeostasis and beta cell function
Bacteroides-derived sphingolipids are critical for intestinal homeostasis and symbiosis, and host sphingolipid regulation participates in this balance. Remodeling ceramide homeostasis promotes functional maturation of human pluripotent stem cell-derived beta cells, connecting GO:0090155 to metabolic cell therapy.
From negative regulation of sphingolipid biosynthetic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does ORMDL3 loss increase de novo sphingolipid synthesis? | ORMDL3 knockout cell line |
| Do SPTLC1 variants escape ORMDL inhibition? | SPTLC1 point-mutation knock-in |
| Can restored ORMDL function rescue sphingolipid overload? | ORMDL overexpression |
| How does SPHK1 catalytic activity affect sphingolipid flux? | SPHK1 point-mutation (kinase-dead) |
| Does ceramide remodeling drive beta cell maturation? | CERS1/CERS2 knockout in iPSC-derived beta cells |
| What is the role of sphingolipid regulation in retinal endothelial cells? | Endothelial-specific knockout or knock-in in retinal models |
How to Study the negative regulation of sphingolipid biosynthetic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Lipidomics (LC-MS/MS) | Sphingolipid species abundance | Quantify ceramides and sphingomyelins after ORMDL manipulation |
| CRISPR knockout screening | Gene requirement for sphingolipid levels | Identify negative regulators of sphingolipid biosynthesis |
| RNA-seq | Transcriptional changes in sphingolipid genes | Profile pathway responses in disease models |
| Proteomics | Protein interactions and abundance | Map ORMDL-SPT complex components |
| Immunofluorescence imaging | Subcellular localization of SPT/ORMDL | Visualize ER-associated sphingolipid synthesis |
| Barrier function assay | Blood-retina barrier integrity | Test sphingolipid regulation in diabetic retinopathy models |
| Beta cell maturation assay | Insulin secretion and ceramide profiles | Study ceramide remodeling in stem cell-derived beta cells |
| Machine learning risk modeling | Sphingolipid gene signatures | Stratify osteosarcoma risk |
Lipidomics and mass spectrometry
Targeted and untargeted lipidomics by mass spectrometry quantify sphingolipid species such as ceramides, sphingomyelins and sphingosine-1-phosphate, providing direct readouts of negative regulation of sphingolipid biosynthetic process.
CRISPR-based genetic screens
CRISPR knockout and activation screens can identify genes that modify sphingolipid levels, including ORMDL family members and SPT subunits, and can be coupled to lipidomic or fluorescent reporters.
Transcriptomics and proteomics
RNA-seq and proteomics reveal expression changes in sphingolipid pathway genes and interacting proteins, helping to map regulatory networks around GO:0090155.
Functional assays in disease models
Barrier function assays in retinal endothelial cells, beta cell maturation assays and intestinal homeostasis models provide physiological context for sphingolipid regulatory mechanisms.
How CRISPR Can Be Used to Study GO:0090155 negative regulation of sphingolipid biosynthetic process
Knockout
CRISPR knockout of ORMDL1, ORMDL2 or ORMDL3 removes the brake on serine palmitoyltransferase and increases de novo sphingolipid biosynthesis, providing a direct test of GO:0090155. Knockout of SPHK1 or ceramide synthases similarly reveals their contributions to sphingolipid homeostasis.
Point Mutation
Point-mutation knock-in of SPTLC1 variants that escape ORMDL inhibition models human macular disease and peripheral neuropathy, allowing precise interrogation of negative regulation of sphingolipid biosynthetic process. Kinase-dead SPHK1 mutants can dissect catalytic versus scaffold functions.
Knock-in
Tagged knock-in of ORMDL or SPT subunits enables localization and interaction studies in live cells, clarifying how the negative regulatory complex assembles on the endoplasmic reticulum. Disease-associated alleles can be introduced into iPSC-derived retinal or neuronal cells.
Overexpression
Overexpression of ORMDL proteins suppresses sphingolipid biosynthesis and can rescue phenotypes caused by excessive sphingolipid flux. Overexpression of SPHK1 or ceramide-metabolizing enzymes shifts the balance of sphingolipid species and tests pathway directionality.
How EDITGENE Supports negative regulation of sphingolipid biosynthetic process Research
Researchers studying negative regulation of sphingolipid biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in sphingolipid homeostasis or is merely correlated with pathway changes. EDITGENE provides validated CRISPR models and bioinformatics support to move from association to mechanism for GO:0090155-related targets such as ORMDL1, ORMDL2, ORMDL3, SPHK1 and SPTLC1.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of sphingolipid biosynthetic process research.
Frequently Asked Questions About negative regulation of sphingolipid biosynthetic process
What is GO:0090155?
GO:0090155 is the Gene Ontology term for negative regulation of sphingolipid biosynthetic process, defined as any process that decreases the rate, frequency or extent of sphingolipid biosynthesis.
What genes are involved in negative regulation of sphingolipid biosynthetic process?
Key genes include ORMDL1, ORMDL2, ORMDL3, SPHK1, SPTLC1, SPTLC2, SPTSSA and SPTSSB, which together control serine palmitoyltransferase activity and sphingolipid flux.
How do ORMDL proteins inhibit sphingolipid biosynthesis?
ORMDL proteins form a complex with serine palmitoyltransferase and reduce its catalytic activity, thereby decreasing de novo sphingolipid synthesis.
What diseases are linked to dysregulated sphingolipid biosynthesis?
Dysregulation has been linked to macular disease, peripheral neuropathy, diabetic retinopathy, osteosarcoma, intestinal inflammation and beta cell dysfunction.
What is the role of SPHK1 in sphingolipid regulation?
Sphingosine kinase-1 interacts with ORMDL proteins to regulate de novo sphingolipid biosynthesis and balance sphingolipid species.
How can CRISPR be used to study GO:0090155?
CRISPR knockout, point-mutation, knock-in and overexpression models can remove or modify ORMDL, SPHK1 and SPTLC1 function to test causal effects on sphingolipid biosynthesis.
Why is negative regulation of sphingolipid biosynthesis important for cell homeostasis?
It prevents excessive production of bioactive sphingolipids such as ceramides, which can cause lipotoxicity, inflammation and metabolic stress.
What methods measure sphingolipid biosynthesis?
Lipidomics by mass spectrometry, RNA-seq, proteomics and functional barrier or beta cell maturation assays are commonly used to measure sphingolipid pathway activity.
Is GO:0090155 relevant to cancer?
Sphingolipid metabolism signatures, including genes related to this process, have been used for osteosarcoma risk stratification, suggesting relevance to cancer biology.
How does the microbiome influence sphingolipid regulation?
Bacteroides-derived sphingolipids are critical for intestinal homeostasis and symbiosis, and host sphingolipid regulation contributes to this balance.
Conclusion
GO:0090155, negative regulation of sphingolipid biosynthetic process, is a biologically important Gene Ontology term that captures the brakes on sphingolipid production, most notably the ORMDL-SPT axis and its interaction with SPHK1. Dysregulation of this process is linked to macular disease, peripheral neuropathy, diabetic retinopathy, osteosarcoma and metabolic dysfunction, making it a compelling target for mechanistic and therapeutic research. CRISPR-based knockout, point-mutation, knock-in and overexpression models, combined with lipidomics and bioinformatics, provide a rigorous path to validate causal genes and restore sphingolipid homeostasis. EDITGENE supports these efforts with validated cell models and screening services tailored to GO:0090155-related research.
References
- 1. Brown EM et al.. 2019. Bacteroides-Derived Sphingolipids Are Critical for Maintaining Intestinal Homeostasis and Symbiosis.. Cell Host Microbe 25(5):668-680.e7 PMID: 31071294
- 2. Yao X et al.. 2024. Specialized Retinal Endothelial Cells Modulate Blood-Retina Barrier in Diabetic Retinopathy.. Diabetes 73(2):225-236 PMID: 37976214
- 3. Zhong Y et al.. 2025. Bayesian Optimization-Enhanced Machine Learning for Osteosarcoma Risk Stratification Based on Sphingolipid Metabolism.. Hum Mutat 2025:2904964 PMID: 40688111
- 4. Hua H et al.. 2024. Remodeling ceramide homeostasis promotes functional maturation of human pluripotent stem cell-derived β cells.. Cell Stem Cell 31(6):850-865.e10 PMID: 38697109
- 5. Siow D et al.. 2015. Regulation of de novo sphingolipid biosynthesis by the ORMDL proteins and sphingosine kinase-1.. Adv Biol Regul 57:42-54 PMID: 25319495
- 6. Brown RDR et al.. 2023. ORMDL in metabolic health and disease.. Pharmacol Ther 245:108401 PMID: 37003301
- 7. Gantner ML et al.. 2019. Serine and Lipid Metabolism in Macular Disease and Peripheral Neuropathy.. N Engl J Med 381(15):1422-1433 PMID: 31509666
- 8. Li B et al.. 2025. Heterogeneity of common carotid artery and abdominal aorta: an angle of sphingolipid metabolism in vascular smooth muscle cells.. Biomed Eng Online 25(1):7 PMID: 41372954
